Validation of the UKPDS 82 risk equations within the Cardiff Diabetes Model

Cost Effectiveness and Resource Allocation

Volumn 13, Issue 1, 2015, Pages

  McEwan, Philip ^a,b   Ward, Thomas ^a   Bennett, Hayley ^a   Bergenheim, Klas ^c  

^a HEALTH ECONOMICS AND OUTCOMES RESEARCH LTD   (United Kingdom)

^b SWANSEA UNIVERSITY   (United Kingdom)

^c ASTRAZENECA R AND D   (Sweden)

Author keywords

Cardiff Diabetes Model; Type 2 diabetes mellitus; UKPDS 82; Validation

Indexed keywords

ARTICLE; CARDIFF DIABETES MODEL; DISEASE MODEL; MATHEMATICAL PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; QUALITY ADJUSTED LIFE YEAR; RISK FACTOR; SIMULATION; UNCERTAINTY; UNITED KINGDOM PROSPECTIVE DIABETES STUDY 82 RISK EQUATION; VALIDATION PROCESS;

EID: 84938696774     PISSN: None     EISSN: 14787547     Source Type: Journal    
DOI: 10.1186/s12962-015-0038-8     Document Type: Article

References (34)

1. International Diabetes Federation (2013) IDF Diabetes Atlas te. IDF Diabetes Atlas, 6th edn. International Diabetes Federation, Brussesl
2. Hex N, Bartlett C, Wright D, Taylor M, Varley D (2012) Estimating the current and future costs of type 1 and type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabet Med J Br Diabet Assoc 29(7):855-862. doi: 10.1111/j.1464-5491.2012.03698.x
3. Brown JB, Palmer AJ, Bisgaard P, Chan W, Pedula K, Russell A (2000) The Mt. Hood challenge: cross-testing two diabetes simulation models. Diabetes Res Clin Pract 50(Suppl 3):S57-S64
4. Mount Hood 4 Modeling G (2007) Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting. Diabet Care 30(6):1638-1646. doi: 10.2337/dc07-9919
5. Palmer AJ, Mount Hood 5 Modeling G, Clarke P, Gray A, Leal J, Lloyd A et al (2013) Computer modeling of diabetes and its complications: a report on the Fifth Mount Hood challenge meeting. Value Health J Int Soc Pharmacoecon Outcomes Res 16(4):670-685. doi: 10.1016/j.jval.2013.01.002
6. van Dieren S, Beulens JW, Kengne AP, Peelen LM, Rutten GE, Woodward M et al (2012) Prediction models for the risk of cardiovascular disease in patients with type 2 diabetes: a systematic review. Heart 98(5):360-369. doi: 10.1136/heartjnl-2011-300734
7. Clarke PM, Gray AM, Briggs A, Farmer AJ, Fenn P, Stevens RJ et al (2004) A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia 47(10):1747-1759. doi: 10.1007/s00125-004-1527-z
8. Kothari V, Stevens RJ, Adler AI, Stratton IM, Manley SE, Neil HA et al (2002) UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke J Cereb Circ 33(7):1776-1781
9. Stevens RJ, Kothari V, Adler AI, Stratton IM, United Kingdom Prospective Diabetes Study G (2001) The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci 101(6):671-679
10. Asche CV, Hippler SE, Eurich DT (2014) Review of models used in economic analyses of new oral treatments for type 2 diabetes mellitus. PharmacoEconomics 32(1):15-27. doi: 10.1007/s40273-013-0117-7
11. Hayes AJ, Leal J, Gray AM, Holman RR, Clarke PM (2013) UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30year United Kingdom Prospective Diabetes Study: UKPDS 82. Diabetologia 56(9):1925-1933. doi: 10.1007/s00125-013-2940-y
12. McEwan P, Peters JR, Bergenheim K, Currie CJ (2006) Evaluation of the costs and outcomes from changes in risk factors in type 2 diabetes using the Cardiff stochastic simulation cost-utility model (DiabForecaster). Curr Med Res Opin 22(1):121-129. doi: 10.1185/030079906X80350
13. Eastman RC, Javitt JC, Herman WH, Dasbach EJ, Copley-Merriman C, Maier W et al (1997) Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care 20(5):735-744
14. Eastman RC, Javitt JC, Herman WH, Dasbach EJ, Zbrozek AS, Dong F et al (1997) Model of complications of NIDDM. I. Model construction and assumptions. Diabetes Care 20(5):725-734
15. McEwan P, Evans M, Bergenheim K (2010) A population model evaluating the costs and benefits associated with different oral treatment strategies in people with type 2 diabetes. Diabetes Obes Metab 12(7):623-630. doi: 10.1111/j.1463-1326.2010.01198.x
16. McEwan P, Evans M, Kan H, Bergenheim K (2010) Understanding the inter-relationship between improved glycaemic control, hypoglycaemia and weight change within a long-term economic model. Diabetes Obes Metab 12(5):431-436. doi: 10.1111/j.1463-1326.2009.01184.x
17. McEwan P, Bergenheim K, Yuan Y, Tetlow AP, Gordon JP (2010) Assessing the relationship between computational speed and precision: a case study comparing an interpreted versus compiled programming language using a stochastic simulation model in diabetes care. PharmacoEconomics 28(8):665-674. doi: 10.2165/11535350-000000000-00000
18. McEwan P, Gordon J, Evans M, Ward T, Bennett H, Bergenheim K (2015) Estimating cost-effectiveness in type 2 diabetes: the impact of treatment guidelines and therapy duration. Med Decis Making. doi: 10.1177/0272989X14565821
19. (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352(9131):837-853
20. Knopp RH, d'Emden M, Smilde JG, Pocock SJ (2006) Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care 29(7):1478-1485. doi: 10.2337/dc05-2415
21. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD et al (2009) Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360(2):129-139. doi: 10.1056/NEJMoa0808431
22. Group AC, Patel A, MacMahon S, Chalmers J, Neal B, Billot L et al (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358(24):2560-2572. doi: 10.1056/NEJMoa0802987
23. Action to Control Cardiovascular Risk in Diabetes Study G, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT et al (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358(24):2545-2559. doi: 10.1056/NEJMoa0802743
24. Griffin SJ, Borch-Johnsen K, Davies MJ, Khunti K, Rutten GE, Sandbaek A et al (2011) Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet 378(9786):156-167. doi: 10.1016/S0140-6736(11)60698-3
25. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M et al (2005) Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366(9489):895-906. doi: 10.1016/S0140-6736(05)67185-1
26. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ et al (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364(9435):685-696. doi: 10.1016/S0140-6736(04)16895-5
27. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B et al (2013) Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369(14):1317-1326. doi: 10.1056/NEJMoa1307684
28. Look ARG, Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM et al (2013) Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 369(2):145-154. doi: 10.1056/NEJMoa1212914
29. Zoppini G, Targher G, Chonchol M, Ortalda V, Negri C, Stoico V et al (2012) Predictors of estimated GFR decline in patients with type 2 diabetes and preserved kidney function. Clin J Am Soc Nephrol CJASN 7(3):401-408. doi: 10.2215/CJN.07650711
30. Hayes AJ, Leal J, Gray AM, Holman RR, Clarke PM (2013) UKPDS Outcomes Model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82. Diabetologia 56(9):1925-1933
31. Law AM (1991) Simulation modeling and analysis. McGraw Hill, New York
32. McEwan P, Foos V, Palmer JL, Lamotte M, Lloyd A, Grant D (2014) Validation of the IMS CORE Diabetes Model. Value Health J Int Soc Pharmacoecon Outcomes Res 17(6):714-724. doi: 10.1016/j.jval.2014.07.007
33. Lundqvist A, Steen Carlsson K, Johansen P, Andersson E, Willis M (2014) Validation of the IHE Cohort Model of type 2 diabetes and the impact of choice of macrovascular risk equations. PloS One 9(10):e110235
34. Eddy DM, Hollingworth W, Caro JJ, Tsevat J, McDonald KM, Wong JB et al (2012) Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7. Value Health J Int Soc Pharmacoecon Outcomes Res 15(6):843-850. doi: 10.1016/j.jval.2012.04.012